Pune, India -- (SBWIRE) -- 03/02/2018 -- Bacterial infection affecting the mucous membrane of the throat and nose is known as diphtheria. The disease can easily spreads from one person to another. It can be prevented through the use of vaccines.

The Global Diphtheria Treatment Market is expected to reach $ 5 billion by the end of 2023, this market is projected to be growing at a CAGR of ~ 3.2 % during 2017-2023.

The bacteria "Corynebacterium diphtheria" causes diphtheria. The disease spreads through person-to-person contact or with objects contaminated with bacteria a cup. It also spreads through sneezing, coughing by the infected person infected person. Thick and gray coating on the throat and tonsils are the common symptom of diphtheria. Other symptoms include a fever, swollen glands in the neck, bluish skin, chills, a sore throat, feeling of uneasiness or discomfort and others.

Key Player:

Sanofi-Pasteur, Taj Pharmaceuticals Limited, Bharat Pharmaceuticals, Merck & Co., GlaxoSmithKline plc, Shanghai Institute of Biological Products, Wuhan Institute of Biological Products, Serum Institute of India, Wyeth and Chiron Pharmaceutical Pvt Ltd. are some of the leading players at the cutting edge of the competition in the market of diphtheria treatment across the globe.

Key Developments:

Companies are now developing new products to capture the market globally. Therefore key market players are investing more in research and development activity, in order to lead the global market. In this regards, market players undertake various strategic approaches.

Get a Brochure of This Report @ https://www.marketresearchfuture.com/sample_request/3828 .

GlaxoSmithKline plc.

GlaxoSmithKline plc is a medical company that develops a varied range of innovative products in three major areas of pharmaceuticals, vaccines and consumer healthcare. The company headquartered at Middlesex, United Kingdom, The company`s product portfolio includes a range of consumer brands, consisting of household names around the world, such as Sensodyne, Aquafresh, Horlicks, Panadol and Tums. The company also operates in the regions such as North America, South and Central America, Europe, Middle East, Asia, Africa and Australia.

December 2016: Innoviva, Inc. and GlaxoSmithKline plc announced that it has permitted Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various indications with chronic obstructive pulmonary disease (COPD) by the Japanese Ministry of Health, Labour and Welfare (MHLW).

November 2016: GlaxoSmithKline plc. & Innoviva, Inc. announced of a new drug application for FF/UMEC/VI in the US of once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol for patients COPD.

December 2015: Nucala (mepolizumab) a product by GlaxoSmithKline plc received grant by European Commission for the authorization for its selling as an add-on treatment for refractory eosinophilic asthma in adult patients. Nucala is approved for use in 31 European countries covered by the European Medicines Agency (EMA).

October, 2015: GlaxoSmithKline plc completed acquisition of Novartis Healthcare's vaccines business thereby enhancing the company's growth in vaccine portfolio.

Grab Attractive Discount @ https://www.marketresearchfuture.com/check-discount/3828 .

Merck & Co.

January 2017: Merck & Co. acquired BioControl to Strengthen Position in Food Safety Testing

August, 2012: Merck & Co. acquired Cell Culture Media Specialist Biochrom AG


Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.